Keros TherapeuticsKROS -0.55%30 Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 151 Biotechnology companies, Keros Therapeutics ranks worse than 662250.99% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Keros Therapeutics is 0.00%.
The historical rank and industry rank for Keros Therapeutics's Dividend Yield % or its related term are showing as below:
KROS's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Keros Therapeutics Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Keros Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KROS vs RNA, RNAC, ARCT: Dividend Yield % Comparison
For the Biotechnology subindustry, Keros Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keros Therapeutics Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's Dividend Yield % falls into.
Keros Therapeutics (KROS) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry.
Is Keros Therapeutics' Dividend Yield % too high?
Keros Therapeutics' current Dividend Yield % is 0.00%. Based on the distribution chart, Keros Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Dividend Yield % compare to RNA and RNAC?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #999999 out of 151 companies for Dividend Yield %. This places Keros Therapeutics in the lower half of its industry. The industry median Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.51, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Keros Therapeutics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keros Therapeutics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Keros Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score
Get the complete analysis for KROS
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KROS has been successfully added to your 
